Department of Anesthesiology, Perioperative, and Pain Medicine, School of Medicine, Stanford University, Stanford, CA 94305, USA.
Department of Anesthesiology, Perioperative, and Pain Medicine, School of Medicine, Stanford University, Stanford, CA 94305, USA.
Trends Mol Med. 2018 Feb;24(2):144-155. doi: 10.1016/j.molmed.2017.12.003.
Alcohol use disorder (AUD) screening frequently involves questionnaires complemented by laboratory work to monitor alcohol use and/or evaluate AUD-associated complications. Here we suggest that measuring aldehyde-induced DNA and protein adducts produced during alcohol metabolism may lead to earlier detection of AUD and AUD-associated complications compared with existing biomarkers. Use of aldehyde-induced adducts to monitor AUD may also be important when considering that approximately 540 million people bear a genetic variant of aldehyde dehydrogenase 2 (ALDH2) predisposing this population to aldehyde-induced toxicity with alcohol use. We posit that measuring aldehyde-induced adducts may provide a means to improve precision medicine approaches, taking into account lifestyle choices and genetics to evaluate AUD and AUD-associated complications.
酒精使用障碍(AUD)的筛查通常涉及问卷和实验室工作,以监测酒精使用情况和/或评估与 AUD 相关的并发症。在这里,我们提出,与现有的生物标志物相比,测量酒精代谢过程中产生的醛诱导的 DNA 和蛋白质加合物可能会更早地发现 AUD 和与 AUD 相关的并发症。当考虑到大约有 5.4 亿人携带乙醛脱氢酶 2 (ALDH2) 的遗传变异,使这部分人群在饮酒时易受到醛诱导的毒性影响时,使用醛诱导的加合物来监测 AUD 可能也很重要。我们假设,测量醛诱导的加合物可能提供一种方法来改善精准医学方法,考虑到生活方式的选择和遗传因素来评估 AUD 和与 AUD 相关的并发症。